Galectin Therapeutics Inc.
Company Snapshot: Galectin Therapeutics Inc.
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.
- Nov 13 2018 Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update
- Nov 5 2018 Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting
- Oct 15 2018 Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference
- Oct 15 2018 Galectin Therapeutics to Present at The ROTH Capital Battle of the NASH Thrones Investment Conference